基本信息
views: 19
Career Trajectory
Bio
Dr Liptrott has a background in pharmacology, immunology and molecular cell biology. His research is focused on investigating biocompatibility, immunocompatibility and haematocompatibility of conventional and nanotechnology-enabled medicines. Dr Liptrott is a member of the Executive Board, as well as core expert team (CET), of the European Nanomedicine Characterisation Laboratory (EU-NCL; http://www.euncl.eu/) for nanoparticle biocompatibility and structure-activity relationships.
Research Interests
Papers共 85 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACYno. 4 (2024): 376-386
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCESno. 10 (2024)
Gary Hannon, Bethany J. Heaton, Alexander Plant-Hately,Christopher David,Neill J. Liptrott,Ainhoa Egizabal, Ana Ayerdi-Izquierdo,Noelia Alvarez, Oihane Ibarrola, Andres Arbona Celaya,Angel Del Pozo Perez, Nerea Lazcanoiturburu, Iris Luzuriagaf, Fikirte Debebe Zegeye, Shanbeh Zienolddiny-Narui,An Jacobs, Alexandra Van Driessche,Inge Nelissen,Ibane Abasolo, Fernanda Andrade,Nora Ventosa, Elisabet Gonzalez-Mira, Aida Carreno, Adriele Prina-Mello
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2023): 114841-114841
Tamiris Borges da Silva,Erika Rendra,Christopher A. W. David,Karen Bieback,Michael J. Cross,Bettina Wilm,Neill J. Liptrott,Patricia Murray
Biomedicine & pharmacotherapy (2023): 115624-115624
Pharmaceuticsno. 7 (2023): 1835-1835
EUROPEAN RESPIRATORY JOURNAL (2023)
Load More
Author Statistics
#Papers: 85
#Citation: 1566
H-Index: 23
G-Index: 37
Sociability: 6
Diversity: 3
Activity: 68
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn